2023 Total Revenue of ~$399.4M, a 21% Increase Year-Over-Year
>2,400 People Living with Fabry Disease on Galafold® Following a Year of Increased Demand
Expecting 2024 Galafold Revenue Growth of 11-16% at CER
Successful Launches of Pombiliti™ + Opfolda™ Underway in the U.S., U.K., and Germany
Mr. Campbell will discuss the Amicus corporate objectives and key milestones in a presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 2:15 p.m. PT. A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.